形肺癌对BRAF和MEK抑制剂治疗的反应:一个病例报告
Hideki Endoh1, Satoshi Wasamoto2
1Department of Thoracic Surgery, Saku Central Hospital Advanced Care Center, Saku, JPN.
Cureus
|March 19, 2025
概括
本案例研究表明,针对多形性癌症,一种困难的非小细胞肺癌的向治疗. BRAF和MEK抑制剂有效地治疗了患有BRAF突变的老年患者,改善了结果.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 肺部病理学 肺部病理学
背景情况:
- 形癌,非小细胞肺癌的一个亚型,提出了重大治疗挑战,往往导致早期复发和不良预后.
- 标准的细胞毒性化疗和免疫疗法在治疗晚期形癌的有效性可能有限.
- 分子分析对于识别非小细胞肺癌中可操作的突变至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K